Documentation Centre

 

 

  of 1227 Next page

Go to page: of

Screenshot Date Categories Title Author Format
Impaired adipose tissue lipid storage, but not altered lipolysis, contributes to elevated levels of NEFA in type 2 diabetes. Degree of hyperglycemia and adiposity are important factors. Metabolism. 2016;65:1768-1780 February 15, 2017 Impaired adipose tissue lipid storage, but not altered lipolysis, contributes to elevated levels of NEFA in type 2 diabetes. Degree of hyperglycemia and adiposity are important factors. Metabolism. 2016;65:1768-1780 Pereira MJ, Skrtic S, Katsogiannos P, Abrahamsson N, Sidibeh CO, Dahgam S, Månsson M, Risérus U, Kullberg J, Eriksson JW Key Publications
The future of lipid guidelines. Curr Opin Lipidol. 2016;27:585-591 February 14, 2017 The future of lipid guidelines. Curr Opin Lipidol. 2016;27:585-591 Robinson JG Key Publications
HDL infusion for the management of atherosclerosis: current developments and new directions. Curr Opin Lipidol. 2016;27:592-596 February 14, 2017 HDL infusion for the management of atherosclerosis: current developments and new directions. Curr Opin Lipidol. 2016;27:592-596 Zheng KH, Stroes ES Key Publications
New oral agents for treating dyslipidemia. Curr Opin Lipidol. 2016;27:579-584 February 13, 2017 New oral agents for treating dyslipidemia. Curr Opin Lipidol. 2016;27:579-584 Gryn SE, Hegele RA Key Publications
Clinical trials with cholesteryl ester transfer protein inhibitors. Curr Opin Lipidol. 2016;27:545-549 February 13, 2017 Clinical trials with cholesteryl ester transfer protein inhibitors. Curr Opin Lipidol. 2016;27:545-549 Di Bartolo BA, Duong M, Nicholls SJ Key Publications
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388:2239-2253 February 08, 2017 Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388:2239-2253 Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S Key Publications
No small task: therapeutic targeting of Lp(a) for cardiovascular disease. Lancet. 2016;388:2211-2212 February 07, 2017 No small task: therapeutic targeting of Lp(a) for cardiovascular disease. Lancet. 2016;388:2211-2212 Feinberg MW Key Publications
Predictive value of triglyceride glucose index for the risk of incident diabetes: A 4-year retrospective longitudinal study. PLoS One. 2016;11:e0163465 February 02, 2017 Predictive value of triglyceride glucose index for the risk of incident diabetes: A 4-year retrospective longitudinal study. PLoS One. 2016;11:e0163465 Lee DY, Lee ES, Kim JH, Park SE, Park CY, Oh KW, Park SW, Rhee EJ, Lee WY Key Publications
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57:1953-1975 January 31, 2017 Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57:1953-1975 Nordestgaard BG, Langsted A Key Publications
Genetic analysis of emerging risk factors in coronary artery disease. Atherosclerosis. 2016;254:35-41 January 31, 2017 Genetic analysis of emerging risk factors in coronary artery disease. Atherosclerosis. 2016;254:35-41 van Iperen EP, Sivapalaratnam S, Holmes MV, Hovingh GK, Zwinderman AH, Asselbergs FW Key Publications

  of 1227 Next page

Go to page: of